Results from the first clinical trial of a drug designed to treat advanced cases of melanoma were successful, and the second part of testing has been approved. 

Although it's extremely rare, melanoma can be found on nearly any surface tissue, from unlikely places like the eye or underneath a fingernail.

While there are entire industries built around adding sunscreen and sunblock to the normal skin products women use, men are far less likely to use skin care products. Why?

Sure, a bronze, suntanned look is youthful and sexy. The thing is, young people - particularly young women - are putting their long-term health at risk by going after that look.

An important part of the scientific process is trying to figure out why common sense beliefs are true. Observing that sun damage and sun burn seemed to cause melanoma still needed solid proof.

Ever since the beginning of modern genetics, scientists believed that DNA encoded for proteins, and every protein had a task. It was that simple.

For years now we've been told to use sunscreen to protect ourselves from too much sun and most importantly skin cancer. Well it turns out one of the ingredients in those lotions could actually be increasing the risk of developing skin cancer. Uh oh.

More than any other factor, early detection of melanoma is key. While you might be more familiar with your moles, apparently fresh eyes are best.

Lymph nodes, the police stations of the human body, are where T cells go to rest, pick up information on recent developments, and get ready to head back out on patrol.

Work in the field of cancer vaccines isn't exactly what you might think. This method of treating cancers coaches the immune system to attack the cancer, not prevent it. A group of researchers successfully concluded two simultaneous trials on a cancer vaccine, finding that it works well in treating patients with both melanoma and ovarian cancer. Using the vaccine increased both length of remission and average lifespan in cancer patients treated. Ask your oncologist about cancer vaccines. The team from the Roswell Park Cancer Institute conducted two parallel phase II clinical ...